 A slew of biopharma stocks are making big moves Tuesday on the back of clinical trial readouts as well announcements regarding MA and tie-ups. Merus, Lilly In 1.68B Oncology Deal: Dutch-based Merus NV NASDAQ: MRUS announced a RD collaboration and licensing agreement with large-cap pharma Eli Lilly And Co NYSE: LLY for developing up to three CD-engaging T-cell redirecting bispecific antibody therapies for oncology indications. 